Abstract
Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARSCoV infection in many countries. The CoV main protease (Mpro), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV Mpros. It is expected that inhibitors targeting CoV Mpros could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.
Keywords: Coronavirus, main protease, drug design
Current Pharmaceutical Design
Title: Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses
Volume: 12 Issue: 35
Author(s): Haitao Yang, Mark Bartlam and Zihe Rao
Affiliation:
Keywords: Coronavirus, main protease, drug design
Abstract: Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARSCoV infection in many countries. The CoV main protease (Mpro), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV Mpros. It is expected that inhibitors targeting CoV Mpros could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.
Export Options
About this article
Cite this article as:
Yang Haitao, Bartlam Mark and Rao Zihe, Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses, Current Pharmaceutical Design 2006; 12 (35) . https://dx.doi.org/10.2174/138161206779010369
DOI https://dx.doi.org/10.2174/138161206779010369 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Pulmonary Ultrasound in COVID-19 Pandemics
Current Respiratory Medicine Reviews Psychological Impact of Coronavirus (COVID-19) Disease on Cancer Patients
Coronaviruses Editorial [Hot Topic:Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Unique nCoV-2019 (Covid-19) Spike Glycoprotein Processing by Host Protease: Analysis and Implication on Infection
Current Proteomics Emerging Therapeutic Approaches to COVID-19
Current Pharmaceutical Design Current Treatments and Therapeutic Options for COVID-19 Patients: A Systematic Review
Infectious Disorders - Drug Targets Vitamin D<sub>3</sub> Deficiency and COVID-19
Coronaviruses Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review
Current Gene Therapy Erythema Pernio-Like in Four Adolescents in the Era of the Coronavirus-2 Infection
Reviews on Recent Clinical Trials Touting Traditional Knowledge and Herbal Medicine to Combat and Prevent COVID-19
Current Pharmaceutical Biotechnology Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical Based Evidence
Current Pharmaceutical Design Machine Learning in Discovery of New Antivirals and Optimization of Viral Infections Therapy
Current Medicinal Chemistry The Role of Celecoxib as a Potential Inhibitor in the Treatment of Inflammatory Diseases - A Review
Current Medicinal Chemistry Current Trends and Future Strategies for the Global Impact of COVID-19 Pandemic
Coronaviruses Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry QT Interval Monitoring and Drugs Management During COVID-19 Pandemic
Current Reviews in Clinical and Experimental Pharmacology Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis
Current Drug Targets Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Flexibility as a Strategy in Nucleoside Antiviral Drug Design
Current Medicinal Chemistry Antiviral Activity and Molecular Targets of Plant Natural Products Against Avian Influenza Virus
Current Organic Chemistry